BOLETÍN HTA

44 / 76

HIPERTENSIÓN / 2017 / VOL. 22
44
Referencias
1. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
2. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? American journal of
hypertension 1996;9:695-9.
3. Elliott WJ, Ram CVS. Calcium Channel Blockers. The Journal of Clinical Hypertension 2011;13:687-9.
4. Opie LH, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on
100 studies. Prog Cardiovasc Dis 2000;43:171-96.
5. Basile J. The Role of Existing and Newer Calcium Channel Blockers in the Treatment of Hypertension. The Journal of Clinical Hypertension 2004;6:621-9.
6. Hypertension in adults: diagnosis and management | Guidance and guidelines | NICE. NICE, 2011. at )
7. Real de Asúa D, Suárez C. Diferencias y similitudes entre los bloqueadores de los receptores del calcio (antagonistas del calcio). Hipertensión y Riesgo
Vascular 2013;30:20-9.
8. Burges RA. Amlodipine: a once daily calcium antagonist. J Hum Hypertens 1991;5 Suppl 1:49-54.
9. Alvarado O. Antagonistas del Calcio en la Hipertension Arterial. Rev Perú Cardiol 1997;XXIII:96-103.
10. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic
function in human hypertension. Hypertension 1995;26:143-9.
11. Law MR, Wald Nj Fau - Morris JK, Morris Jk Fau - Jordan RE, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs:
analysis of 354 randomised trials. BMJ 2003;326:1427.
12. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens
2009;23:503-11.
13. Jorgensen MG. Prevalence of Amlodipine-Related Gingival Hyperplasia. Journal of Periodontology 1997;68:676-8.
14. American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians
and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-31.
15. Bramham K, Nelson-Piercy C, Brown MJ, Chappell LC. Postpartum management of hypertension. BMJ 2013;346:f894.
16. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic
hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
17. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension.
Systolic Hypertension in China (Syst-China) Collaborative Group. Journal of hypertension 1998;16:1823-9.
18. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients
randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
19. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or
amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
20. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes
Trial. ASCOT investigators. Journal of hypertension 2001;19:1139-47.
21. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required
versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):
a multicentre randomised controlled trial. Lancet 2005;366:895-906.
22. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on
cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
23. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE)
trial. JAMA 2003;289:2073-82.
24. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies:
a meta-analysis of randomised controlled trials. Lancet 2000;356:1949-54.
25. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to
conventional therapy. J Am Coll Cardiol 2002;39:315-22.
26. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. Journal
of hypertension 2003;21:1055-76.
27. Turnbull F, Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results
of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
28. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
29. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management
of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
30. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members
appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20.
31. Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Archives of
internal medicine 2001;161:1145-58.
32. Nissen SE, Tuzcu E, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood
pressure: The camelot study: a randomized controlled trial. JAMA 2004;292:2217-25.
33. Ando K. L-/N-type calcium channel blockers and proteinuria. Current hypertension reviews 2013;9:210-8.
34. Loutzenhiser RD, Epstein M, Fischetti F, Horton C. Effects of amlodipine on renal hemodynamics. American Journal of Cardiology;64:I122-I8.
35. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
The New England journal of medicine 2001;345:861-9.
36. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
The New England journal of medicine 2001;345:861-9.
37. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. The New England journal of medicine 2004;351:1941-51.
38. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression.
Kidney international 2004;65:1991-2002.
39. Valdes G, Roessler E, Sociedad Chilena de Hipertension A. [Recommendations for the management of hypertensive crisis. A Consensus document of
the Chilean Society of Hypertension]. Rev Med Chil 2002;130:322-31.